FDA Clarification Of Health Claims "Scientific Agreement" Standard Ordered
This article was originally published in The Tan Sheet
Executive Summary
Clarification by FDA of the "significant scientific agreement" standard it uses to evaluate health claims for dietary supplements was ordered by a federal appeals court in a Jan. 15 decision.
You may also be interested in...
FDA Prohibition of Saw Palmetto/BPH Treatment Claim Upheld by Court
FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hypertrophy symptoms was upheld by a Washington, D.C. federal court in a Jan. 3 decision
FDA Prohibition of Saw Palmetto/BPH Treatment Claim Upheld by Court
FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hypertrophy symptoms was upheld by a Washington, D.C. federal court in a Jan. 3 decision
FDA Prohibition of Saw Palmetto/BPH Treatment Claim Upheld by Court
FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hypertrophy symptoms was upheld by a Washington, D.C. federal court in a Jan. 3 decision